DDL 2023

December 7-9 | Edinburgh, Scotland

Proveris is a sponsor, exhibitor, and poster presenter at the Drug Delivery to The Lungs (DDL) conference which will be held December 7-9. 

If you would like to learn more and schedule a meeting with us, email us at contactus@proveris.com.

Drug Delivery to the Lungs (DDL) is an annual conference covering all aspects of respiratory drug delivery. It attracts a wide variety of attendees, including scientists, academics, clinicians, regulators, and industry experts. It offers a venue for lectures, posters, and exhibitions.

Learn more and register HERE.

IRDD US Congress 2023

October 2-3 | San Diego, USA

Proveris experts will give a presentation and meet with attendees as an exhibitor at the 5th Annual Inhalation & Respiratory Drug Delivery US (IRDD US) Congress.

If you would like to learn more and schedule a meeting with us, email us at contactus@proveris.com.

The IRDD US Congress delivers breakthrough research, technologies & connects global pharma, biotech and academia for high-level discussions on the latest innovations in formulation, drug delivery & inhaled science.

Exceptional speakers discuss the latest challenges and innovations in inhaled therapies formulation, delivery and moving towards sustainable device development

Learn more and register HERE.

8th Pulmonary Drug Delivery

May 31-June 2 | Istanbul, Turkey

Proveris is a presenter at the 8th Drug Delivery Workshop which will be held from May 31-June 2.

Our presentation entitled ‘Spray Characterization for In Vitro Bioequivalence’ will be given by Dr. Deborah Jones, EMEA Director of Sales. The presentation focus is on in vitro nasal drug development solutions for the Turkish pharma market and will include new measurements of interest for pMDI and Soft Mist drug development.

If you would like to learn more and schedule a private meeting with us, email us at contactus@proveris.com.

The Pulmonary Drug Delivery Workshop (PDD) series aim is to provide a space for discussions on research and engagement in new collaborations. It’s a forum for learning about inhalation drug delivery from leaders in the field and discuss aerosol-related topics in a relaxed atmosphere. 

Learn more and register HERE.

Novel Formulation & Delivery Summit

May 17-18 | San Diego, USA

Proveris is an expertise sponsor of The Novel Formulation & Delivery Summit which will be held from May 17-18.

Our presentation entitled ‘Using Quality by Design (QbD) to Accelerate Nasal Drug Product Development’ discusses in vitro testing approaches that accommodate the complexity of combination products. The approach incorporates QbD into the very early development phase and facilitates a streamlined scale-up during commercialization.

If you would like to learn more and schedule a private meeting with us, email us at contactus@proveris.com.

The Novel Nasal Formulation & Delivery Summit is a unique forum set to unite 60 plus pioneers in nasal drug development. Speakers will reveal enlightening content focusing on novel formulation and delivery techniques for both acute and chronic disease indications. Attendees will learn how to propel non-invasive therapeutics through nasal drug delivery route and increase patient adherence across the next generations of vaccines, CNS, and respiratory indications.

Learn more and register HERE.

RDD Europe 2023

May 2-5 | Nice, France

Proveris is an exhibitor, workshop presenter, and poster presenter at the Respiratory Drug Delivery (RDD 2023) which will be held in-person and as a virtual event from May 2-5.

Our workshop presentation entitled ‘Synergies of Inhalation Product Development and Spray Characterization’ is in collaboration with Catalent Inhalation. Our poster presentation entitled ‘Comparison of Spray Characteristics of pMDIs with P-134a (current Propellant) and Low-GWP P-152a Propellant with 8% Ethanol and Ethanol-free’ is in collaboration with Koura Global.

If you would like to learn more and schedule a private meeting with us, email us at contactus@proveris.com.

Respiratory Drug Delivery, RDD®, is an international conference for researchers, regulators, business professionals and suppliers active in pulmonary and nasal drug delivery. It provides a venue for expert speakers to cover topics including new therapeutic opportunities, drug delivery technologies, regulatory science, and novel in vitro, in vivo and clinical testing methods.

Learn more and register HERE.

Proveris Scientific welcomes back Alyssa Rubino as Technical Data Scientist for Proveris Laboratories

Proveris Scientific Corporation, a leading provider of services and technology to advance the science of spray and aerosol products, today announced that it has increased the level of customer support by expanding its laboratory services organization with the addition of Technical Data Scientist, Alyssa Rubino.

Alyssa rejoins the Proveris Laboratories team where for years she provided guidance, not only in designing protocols that allowed complete and efficient characterization of oral and nasal devices, but also in completing data analysis to best leverage the information and accelerate the achievement of project goals. She will report to the Director of Application and Business Development for Proveris Laboratories, Maria Smith. The combination of their talents will provide a broader and more in-depth support offering.

Alyssa will be responsible for ensuring appropriate study design, compiling and analyzing analytical study data, deriving conclusions and key information, and generating reports for all contracted projects to ensure they meet internal, customer, and regulatory standards. Alyssa has more than 10 years of experience in applications engineering, product management, and operations gained from her time with industry leaders such as Tekscan, Ocular Therapeutix, and, of course, Proveris. Utilizing her knowledge, Alyssa will also help drive the implementation of new technologies into Proveris Laboratories and expand the laboratory service offering.

Alyssa holds a Bachelor of Science in Mechanical Engineering from Northeastern University and has co-authored 5 publications on the science of orally inhaled and nasal drug products.

About Proveris Scientific:

Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving new technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, China NMPA (National Medical Products Administration), and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TUV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.

 

DDL 2022

December 7-9, 2022 | Edinburgh, Scotland

Proveris will sponsor this year’s Drug Delivery to The Lungs (DDL) conference which will be held December 7-9. Attendees to our exhibit will be able to explore new tools for spray characterization, studies for predictive in vitro / in vivo correlation, and precision automated actuation technology for through-life testing.

If you would like to learn more and schedule a meeting with us,
email us at contactus@proveris.com.

Drug Delivery to the Lungs (DDL) is an annual conference covering all aspects of respiratory drug delivery. It attracts a wide variety of attendees, including scientists, academics, clinicians, regulators and industry experts. It offers a venue for lectures, posters and exhibitions.

IDDS 2022

October 27-29 | Suzhou China

Proveris is a platinum sponsor of the 9th Innovative Drug Delivery Solution Summit (IDDS 2022) which will be held in-person from October 27-29 in Suzhou, China.

Proveris Scientific’s partner, Ruty Li of Quantaflux, will attend IDDS. He will be at the Proveris table in the exhibit area and will give a scientific presentation on behalf of Proveris. The presentation will cover analytical instrumentation and testing strategies for pressurized meter dose inhalers (pMDI’s), soft mist inhalers (SMI’s) and unit-dose nasal sprays.

If you would like to learn more and schedule a meeting with him, email us
at contactus@proveris.com.

The 9th Innovative Drug Delivery Solution Summit (IDDS·2022) which cover three special sessions, including regulatory trends and technologies for complex preparations, active packaging technology empowers pharma-cos and innovative packaging for consumer health goods, will be held online and offline during Oct and Nov. The session of regulatory trends and technologies for complex preparations will take place in Suzhou will be open to the biopharmaceutical enterprises and industry peers free of charge. Regulatory trends and technologies for high-end pharmaceutical preparations session of IDDS·2022 will invite regulatory, clinical, pharmaceutical, market experts, and industrial leading players, involve four parallel sessions: regulations and market trends, nasal to brain drug delivery, inhalation formulations and sterile formulations.

3rd Annual Inhalation & Respiratory Drug Products

September 8-9 | Proveris is a sponsor of the 3rd Annual Inhalation and Respiratory Drug Delivery Conference which, which will be held in-person from September 8-9.

Proveris Sales Director, Dr. Deborah Jones, will give a keynote speaker presentation exploring the evidence generic drug developers need to support ANDA approval for their pressurized metered dose inhaler or soft mist inhaler drug product without a clinical trial. It will focus on the in vitro spray characterization approaches; Plume Front Velocity, Spray Duration and Evaporation Fraction/Rate. It will provide data highlighting how these measurements can provide key insights that will accelerate the development process with the goal of getting products to market most efficiently.   

The 3rd Annual Inhalation and Respiratory Drug Delivery Conference is modeled for senior manager representatives, experts and main decision makers who are interested to be acquainted with the latest approaches and inventions of the respiratory drug products delivery field. It will cover the latest innovations and trends in inhalation and respiratory market, formulation & delivery of inhaled therapies, the new challenges and approaches of the inhaler models and technologies. The agenda will include content on global regulatory CMC requirements, key studies on the latest trends in inhalation devices and personalized treatments with large and small molecules for different respiratory diseases. Presentations will be focused on the topics, such as: cell therapy, inhaled vaccines and the future potential for high-dose applicants and available liquid inhalation devices. 

Learn more and register visit HERE.

Proveris Scientific names Ramesh Chand as Associate Director of rapidly growing GMP contract test business, Proveris Laboratories

Proveris Scientific Corporation, a leading provider of instrumentation and services to advance the science of aerosol and spray products, today announced Ramesh Chand has been named Associate Director of Proveris Scientific’s rapidly growing GMP contract test business, Proveris Laboratories.

Ramesh Chand is a scientific expert with more than 16 years of professional experience within the Orally Inhaled and Nasal Drug Product (OINDP) development community, including analytical, formulation development, process development, device selection and characterization, scale-up/technical transfer and preclinical aerosol development on both innovator and generic drug products. His work also encompasses nebulization and nose-to-brain nasal delivery of biologics. As Associate Director of Proveris Laboratories, he will oversee the day-to-day laboratory operations, ensuring quality and regulatory standards are upheld and will assist Proveris Research in introducing innovative technologies to advance inhalation science and development. His diverse expertise will shape strategic direction and will allow Proveris to expand their menu of services.

Ramesh earned his Master of Science in chemical engineering, from Missouri University of Science and Technology, which included thesis work focused on ‘Generation and Characterization of Aerosols.’ Prior to joining Proveris, he worked for Moderna Therapeutics in Cambridge, MA as the Principal Scientist of Drug Product Development (Respiratory), Amneal Pharmaceuticals, Piscataway, NJ as a Senior Research Scientist, Inhalation Product Development, Lovelace Biomedical, Albuquerque, NM as Senior Research Associate and GlaxoSmithKline, Research Triangle Park, NC as an Associate Scientist, Inhaled Product Development. With his regular contributions to research, Ramesh has co-authored more than 15 respiratory articles.

“Ramesh is a significant addition to the Proveris Laboratories team,” commented Dino Farina, CEO, Proveris Scientific. “His experience in OINDP drug development combined with his research will provide our customers access to proven expertise that will help them achieve their goals quickly and at the highest quality. In addition, he will be a key player in helping Proveris Research deliver new and innovative technologies through Proveris Labs for the advancement of inhalation science and drug development”

Ramesh added, “I am excited to join Proveris at a time when the company is rapidly advancing the test services business. Proveris is uniquely positioned in supporting OINDP development programs. I believe the addition of innovative technologies and expanded capabilities will immensely benefit customer’s respiratory drug development.”

About Proveris Scientific
Proveris Scientific Corporation advances the science of respiratory drug delivery products by driving innovative technology development for high performance spray characterization, capture, and analysis, while leveraging its expertise, experience, and core technologies. With customer success as its central motivating force, Proveris Scientific adds value to a global customer base with “complete solutions” which include product innovation, technical services, systems, consumables, and educational training. Since its founding in 1995, the company has accelerated the development of top spray and aerosol drug products and has deployed its systems at more than 100 pharmaceutical development and manufacturing sites around the globe. Proveris’s systems are the industry standard and are used by the FDA, CFDA, and the pharmaceutical industry to generate submission-ready data. Proveris is certified to ISO 9001:2015 by TÜV Rheinland of North America, Inc., and has more than 20 patents issued on its technology.